ArticleHeliyon2025
A novel signature predicts prognosis in pancreatic cancer based on tumor membrane-associated genes.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Automatic Blood Protein Enrichment by Magnetic-COF Polymers.Analytical chemistry · 2026Article
- Integrative multimodal transcriptomics identifies a cancer-associated fibroblast membrane signature for predicting prognosis and therapeutic response in pancreatic ductal adenocarcinoma.Journal of molecular medicine (Berlin, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer is one of the leading causes of tumor-related mortality, characterized by short patient survival times and limited treatment options. Some targeted therapies have not succeeded in improving patient prognosis. Tumor membranes possess potential target specificity, offering hope for enhancing the efficacy of immunotherapy and drug treatment. Methods: In this study, we collected gene expression and survival data from two scRNA-seq projects and patient cohorts in TCGA, ICGC, and GEO. Differential analysis and dimensionality reduction clustering were employed to isolate tumor epithelial cells. High-expression membrane-associated genes in tumor epithelial cells were identified through PPI network analysis and functional enrichment. Subsequently, membrane-associated genes associated with patient prognosis were selected using LASSO and Cox regression to construct MaGPS, which was validated in external datasets. Potential therapeutic targets of the MaGPS signatures were identified and confirmed by integrating spatial transcriptomics, scRNA-seq, and protein expressions. In addition, drug sensitivity analysis was performed to explore potential targeted drugs associated with MaGPS. Results: The results demonstrated the identification of a specific tumor epithelial cell cluster, c0. This cluster expressed 17 membrane-associated genes that are closely interconnected and play roles in extracellular interactions. The MaGPS model, developed based on the membrane-associated genes Conclusion: The MaGPS model, based on bulk RNA-seq, scRNA-seq, and spatial transcriptomics data, effectively evaluated the prognosis of pancreatic cancer and provided valuable insights for better therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.